Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients
NCT02022709 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 78
Last updated 2022-09-09
Summary
The purpose of this study is to evaluate the efficiency of SSRIs(Selective Serotonin Reuptake Inhibitor) ,ERP(Exposure and Response Prevention) and the combination of the two therapies for OCD(Obsessive-Compulsive Disorder) patients ,at the same time, to find out the biological or psychological predictors of treatment response in Chinese population.
Conditions
- Obsessive-Compulsive Disorder
- Anxiety Disorders
- Mental Disorders
Interventions
- DRUG
-
Fluoxetine
The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
- DRUG
-
Sertraline
The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
- DRUG
-
Paroxetine
The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
- DRUG
-
Citalopram
The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
- DRUG
-
Fluvoxamine
The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
- BEHAVIORAL
-
Exposure and Response Prevention
8 exposure and response prevention (ERP) sessions,once a week
Sponsors & Collaborators
-
Shanghai Municipal Science and Technology Commission
collaborator OTHER_GOV -
Shanghai Jiao Tong University School of Medicine
collaborator OTHER -
Shanghai Mental Health Center
lead OTHER
Principal Investigators
-
Zhen Wang, Ph.D, M.D · Shanghai Mental Health Center
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 16 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2014-01-31
- Primary Completion
- 2017-11-18
- Completion
- 2018-03-13
Countries
- China
Study Locations
More Related Trials
-
Citalopram and Stress Reactivity
NCT04161209 ·Status: UNKNOWN ·Phase: NA
-
Serotonin, Anxiety and Visceral Sensation
NCT06212284 ·Status: COMPLETED ·Phase: NA
-
Treatment Trial for Psychogenic Nonepileptic Seizures
NCT00835627 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Single Dose Citalopram and Reboxetine on Urethral and Anal Closure Function on Healthy Female Subjects
NCT04097288 ·Status: COMPLETED ·Phase: PHASE1
-
Double Blind Randomized, Monocentric, Cross-over, Placebo-controlled Study to Evaluate the Effect of Citalopram on Motivation
NCT02113943 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Fluoxetine in Adults With Autistic Disorder
NCT00027404 ·Status: COMPLETED ·Phase: NA
-
Brain Response to Serotonergic Medications in ASD
NCT04145076 ·Status: UNKNOWN ·Phase: NA
-
Compare the Efficacy and Tolerability of the Combination of Aripiprazole and Selective Serotonin Reuptake Inhibitors (SSRIs) Used in Major Depression
NCT00873795 ·Status: COMPLETED ·Phase: NA
-
Identifying Brain and Genetic Markers of Sertraline Treatment Response in People With Social Anxiety Disorder
NCT00872131 ·Status: COMPLETED
-
Repetitive Behavior Disorders in People With Severe Mental Retardation
NCT00491478 ·Status: UNKNOWN ·Phase: PHASE3
-
Fluvoxamine and Sertraline in Childhood Autism - Does SSRI Therapy Improve Behaviour and/or Mood?
NCT00655174 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment of Mild and Subthreshold Depressive Disorders
NCT00226642 ·Status: UNKNOWN ·Phase: PHASE4
-
REward Processing And Citalopram Study
NCT06017037 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Antidepressant Controlled Trial for Negative Symptoms in Schizophrenia
NCT01032083 ·Status: COMPLETED ·Phase: PHASE4
-
A Comparison of Sertraline-reboxetine Combination Therapy Versus Sertraline or Reboxetine Monotherapy in the Treatment of Major Depression.
NCT00636246 ·Status: COMPLETED ·Phase: PHASE2
-
Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia
NCT01300364 ·Status: UNKNOWN ·Phase: PHASE4
-
Study Of Indiplon/Placebo With Sertraline In Insomnia Co-Existing With Depression
NCT00232167 ·Status: TERMINATED ·Phase: PHASE3
-
Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence
NCT00330239 ·Status: COMPLETED ·Phase: PHASE4
-
Phase II Study of Stereotypes and Mental Retardation: Neurobiological Basis
NCT00004300 ·Status: SUSPENDED ·Phase: PHASE2
-
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant
NCT04533529 ·Status: COMPLETED ·Phase: PHASE3
-
TC-5214 as add-on the Treatment of Major Depressive Disorder
NCT00692445 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Sertraline to Prevent PTSD
NCT00182078 ·Status: COMPLETED ·Phase: PHASE4
-
Aripiprazole for the Augmentation of Antidepressant Therapy
NCT01429831 ·Status: COMPLETED ·Phase: PHASE4
-
Inflammatory Control of Antidepressant Efficacy: a Pharmaco-epigenetic Approach
NCT06306209 ·Status: RECRUITING
-
Cognitive Flexibility in Major Depression in the Course of Pharmacological and Psychotherapeutic Treatment
NCT00993876 ·Status: COMPLETED ·Phase: NA